ANCA ASSOCIATED VASCULITIS
Clinical trials for ANCA ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising CAR-T trial for kids with rare vasculitis pulled before start
Disease control TerminatedThis trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for ch…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney failure patients may ditch immune drugs in landmark trial
Disease control OngoingThis study looks at whether people with ANCA vasculitis who have reached end-stage kidney disease can safely stop taking immunosuppressive medications. The goal is to see if stopping these drugs lowers the risk of serious infections and other side effects without causing dangerou…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control TerminatedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control TerminatedThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC